CliffBio
small molecule

VYLEESI (AUTOINJECTOR)

BREMELANOTIDE ACETATE

Loss of exclusivityApril 2041latest FDA-listed patent expiry
CompanyCosette Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameVYLEESI (AUTOINJECTOR)
Active ingredientBREMELANOTIDE ACETATE
StrengthEQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalJune 2019
Marketing statusRX

Listed patents

PatentExpiresType
11590209April 2041use U-3539
9352013November 2033use U-2568
9700592November 2033use U-2568
10286034November 2033use U-2568

More from Cosette Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VYLEESI (AUTOINJECTOR) patent cliff — loss of exclusivity April 2041 | CliffBio